UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934 (Amendment No. 2)

ALLOGENE THERAPEUTICS, INC.

(Name of Issuer)

Common Stock (Title of Class of Securities)

019770 10 6 (CUSIP Number)

December 31, 2020 (Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☒ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CCSII	110.01	7110	150	1 450 2 01 3 1 450
1	Names	s of I	Reporting Persons	
	Seavie	w Tı	ust	
2	Check the Appropriate Box if a Member of a Group			
	(a) 🗆		(b) 🗆	
3	SEC Use Only		nly	
4	Citizenship or Place of Organization			
	Califo	California		
		5	Sole Voting Power	
Number of			7,340,867 Shares	
Shares		6	Shared Voting Power	
Beneficially Owned by			0	
Each		7	Sole Dispositive Power	
Reporting				
Person With:		0	7,340,867 Shares	
,	V 1611.	8	Shared Dispositive Power	
			0	
9 Aggregate Amount Beneficially Owned by Each Reporting Person				
7,340,867 Shares		hares		
10	0 Check if the Aggregate Amount in Row (9) Excludes Certain Shares			
11	Percent of Class Represented by Amount in Row (9)			
	5.2% (1)			
12	Type of Reporting Person			
	00			

(1) This percentage is calculated based on 140,280,152 shares of common stock outstanding as of November 2, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 4, 2020.

Item 1(a). Name of Issuer:

Allogene Therapeutics, Inc.

Item 1(b). Address of Issuer's Principal Executive Offices:

210 East Grand Avenue South San Francisco, CA 94080

Item 2(a). Names of Persons Filing:

Seaview Trust

Item 2(b). Address of Principal Business Office, or, if none, Residence:

811 Strada Vecchia Road, Los Angeles, CA 90077

Item 2(c). Citizenship:

California

Item 2(d). Title of Class of Securities:

Common Stock

Item 2(e). CUSIP No.:

019770 10 6

Item 3. Not Applicable.

Item 4. Ownership

The information requested is set forth in items 5 through 9 and 11 of the cover page to this Schedule 13G. Ownership is stated as of December 31, 2020. This percentage is calculated based on 140,280,152 shares of common stock outstanding as of November 2, 2020, as reported in the Issuer's Quarterly Report on Form 10-Q filed on November 4, 2020.

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof, the Reporting Persons have ceased to be the beneficial owner of more than five percent of the class of securities, check the following: \Box

Item 6. Ownership of More than Five Percent on Behalf of Another Person

Not applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person

Not applicable

Item 8. Identification and Classification of Members of the Group

Not applicable

Item 9. Notice of Dissolution of Group

Not applicable

Item 10. Certifications

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 11, 2021

Seaview Trust

By: /s/ Hanna Ackerman

Name: Hanna Ackerman, Trustee